Association between genetic variants in FADS1-FADS2 and ELOVL2 and obesity, lipid traits, and fatty acids in Tunisian population

Khamlaoui, Wided; Mehri, Sounira; Hammami, Sonia; Hammouda, Souha; Chraeif, Imed; Elosua Llanos, Roberto; Hammami, Mohamed

doi:http://dx.doi.org/10.1177/1076029620915286

Association between genetic variants in FADS1-FADS2 and ELOVL2 and obesity, lipid traits, and fatty acids in Tunisian population

License

Citation

Khamlaoui W, Mehri S, Hammami S, Hammouda S, Chraeif I, Elosua R, et al. Association between genetic variants in FADS1-FADS2 and ELOVL2 and obesity, lipid traits, and fatty acids in Tunisian population. Clin Appl Thromb Hemost. 2020 Jan-Dec; 26 :1076029620915286. DOI: 10.1177/1076029620915286

Abstract

The aim of this study was to determine whether genetic variants in FADS1/FADS2 and ELOVL2 are associated with overweight-obesity and body mass index (BMI) and to assess the association between these genetic variants and lipid profile and fatty acid levels. A total of 259 overweight-obese patients were compared to 369 healthy controls. FADS1, FADS2, and ELOVL2 genes were associated with BMI and overweight-obesity (P ≤ .001). In an additive model, the C allele in each of these variants was associated with a lower BMI: -1.18, -0.90, and -1.23 units, respectively. Higher amounts of total cholesterol, low-density lipoprotein cholesterol, total saturated fatty acids (lauric [12:0], myristic [C14:0], palmitic [C16:0], stearic [C18:0], arachidic [20:0], lignoceric [24:0]), monounsaturated fatty acids (myristoleic [C14:1], erucic [C22:1 n-9]), and polyunsaturated fatty acids (α-linolenic [ALA, 18:3 n-3], docosahexaenoic [DHA, C22:6 n-3], eicosapentaenoic acid [EPA, C20:5n-3], arachidonic acid [AA, 20:4n-6], and conjugated linolenic acids [CLA1 and CLA2]) were shown in patients. A significant increase in D6D activities presented by 20:4n-6/18:2n-6 and 18:3n-6/18:2n-6, Δ9 desaturase (D9D) activity, estimated by the ratio 18:1n-9/18:0 and elongase activities (AE), and estimated by the ratio of docosatetraenoic/AA and DPA/EPA in patients. The C minor allele of FADS1 had significantly lower DHA. A significant decrease in stearic acid, EPA, and AE activity (docosatetraenoic/AA) was revealed in patients with the minor allele carriers of FADS2. The C minor allele of ELOVL2 had significantly lower ALA, EPA, DPA, and D6D activity (C20:4 n-6/C18:2n-6). These data suggest that variations in FADS1, FADS2, and ELOVL2 affect the risk of overweight-obesity and the level of circulating fatty acids and could point to a key molecular pathway of metabolic syndrome and its related comorbidities.